Espa?ol
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Immunotherapy is the use of medicines to help a person's own immune system find and destroy cancer cells more effectively.
An important part of the immune system is its ability to prevent itself from attacking normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells, which act like switches that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system.
Drugs that target these checkpoints (called immune checkpoint inhibitors) can be used to treat some people with stomach cancer (also known as gastric cancer).
Nivolumab (Opdivo) and pembrolizumab (Keytruda) are drugs that target PD-1, a protein on immune system cells called T cells. The PD-1 protein normally helps keep T cells from attacking other cells in the body. By blocking PD-1, these drugs boost the immune response against cancer cells. This can shrink some tumors or slow their growth.
Nivolumab can be used in people with advanced stomach cancer, typically along with chemotherapy.
This drug is given as an intravenous (IV) infusion, usually once every 2 or 3 weeks.
Pembrolizumab can be used as part of the first treatment for people with advanced stomach cancer, either:
This drug can also be used after other treatments including chemotherapy have been tried, and if the cancer cells test positive for any of the following:
This drug is given as an intravenous (IV) infusion, typically once every 3 or 6 weeks.
Side effects of these drugs can include:
Other, more serious side effects occur less often. These can include:
Infusion reactions: Some people might have an infusion reaction while getting one of these drugs. This is like an allergic reaction, and can include fever, chills, flushing of the face, rash, itchy skin, feeling dizzy, wheezing, and trouble breathing. It’s important to tell your doctor or nurse right away if you have any of these symptoms while getting one of these drugs.
Autoimmune reactions: These drugs work by basically removing one of the safeguards on the body’s immune system. Sometimes this causes the immune system to attack other parts of the body, which can lead to serious or even life-threatening problems in the lungs, intestines, liver, hormone-making glands, kidneys, skin, or other organs.
It’s very important to report any new side effects to your health care team right away. If serious side effects do occur, treatment may need to be stopped and you may get high doses of corticosteroids to suppress your immune system.
To learn more about how drugs that work on the immune system are used to treat cancer, see Cancer Immunotherapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Bendell J, Yoon HH. Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: Approach to later lines of systemic therapy. UpToDate. 2020. Accessed at https://www.uptodate.com/contents/progressive-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer-approach-to-later-lines-of-systemic-therapy on July 13, 2020.
Ku GY, Ilson DH. Chapter 72: Cancer of the Stomach. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
National Cancer Institute. Physician Data Query (PDQ). Gastric Cancer Treatment. 2020. Accessed at: https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq on July 13, 2020.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2020. Accessed at www.nccn.org/professionals/physician_gls/pdf/gastric.pdf on July 13, 2020.
Last Revised: November 21, 2023
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.